文献速递糖尿病

短期艾塞那肽餐时给药对1型糖尿病血糖控制的疗效与安全性(MAG1C):一项随机双盲安慰剂对照试验

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-03-02

MAG1C试验在108例每日多次注射治疗的1型糖尿病患者中比较餐时皮下注射艾塞那肽10μg每日三次与安慰剂26周的疗效。主要终点HbA1c组间差异为-1.1 mmol/mol(95%CI -3.4至1.2;p=0.36),未达统计学显著。艾塞那肽组自我报告的胃肠道不良事件增多,主要为恶心。

要点

  • 26周时艾塞那肽组HbA1c变化-3.2 mmol/mol(95%CI -5.0至-1.4),安慰剂组-2.1 mmol/mol(-3.7至-0.6)。
  • 组间估计治疗差异为-1.1 mmol/mol(95%CI -3.4至1.2;p=0.36),未达统计学显著。
  • 艾塞那肽组自我报告的胃肠道不良事件增多,主要为恶心(艾塞那肽组37例患者共48起事件,安慰剂组9例患者共9起事件)。

核心结论

  • 短期艾塞那肽似乎不适合作为1型糖尿病胰岛素治疗的标准附加治疗。

研究设计与样本

  • 单中心、平行组、随机、双盲、安慰剂对照试验(MAG1C),纳入108例每日多次注射治疗的1型糖尿病患者,按1:1随机分配至餐时皮下注射艾塞那肽10μg或安慰剂每日三次,共26周,作为常规胰岛素治疗的附加治疗。

主要发现

  • 26周后,基线校正后HbA1c在艾塞那肽组变化-3.2 mmol/mol(95%CI -5.0至-1.4),安慰剂组变化-2.1 mmol/mol(95%CI -3.7至-0.6)。
  • 组间估计治疗差异为-1.1 mmol/mol(95%CI -3.4至1.2;p=0.36)。
  • 艾塞那肽组自我报告的胃肠道不良事件增多,主要为恶心(艾塞那肽组37例患者共48起事件,安慰剂组9例患者共9起事件)。
  • 艾塞那肽组发生2起严重不良事件,安慰剂组发生6起,均被认为与研究药物无关。

临床怎么用

  • 原文结论认为短期艾塞那肽似乎不适合作为1型糖尿病胰岛素治疗的标准附加治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In type 2 diabetes, long-acting GLP-1 receptor agonists lower fasting plasma glucose and improve glycaemic control via their insulinotropic and glucagonostatic effects. In type 1 diabetes, their efficacy as an add-on treatment to insulin therapy is modest. Short-acting GLP-1 receptor agonists also lower postprandial glucose excursions in type 2 diabetes by decelerating gastric emptying rate. We aimed to test the efficacy of a short-acting GLP-1 receptor agonist in type 1 diabetes. METHODS: In the single-centre, parallel-group, randomised, double-blind, placebo-controlled MAG1C trial, patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older with HbA1c 59-88 mmol/mol (7·5-10·0%) and a BMI of more than 22·0 kg/m2 were randomly assigned (1:1) through a computer-generated randomisation list to preprandial subcutaneous injection of 10 μg exenatide (Byetta) or placebo three times daily for 26 weeks as an add-on treatment to usual insulin therapy. Clinically assessed insulin titration was done by study staff. Participants and investigators were masked to treatment allocation. The primary endpoint was between-group difference in HbA1c after 26 weeks. Data were analysed with a baseline-adjusted linear mixed model in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03017352, and is completed. FINDINGS: Between Jan 4, 2017, and Jan 16, 2019, 108 participants were randomly assigned, 54 to exenatide and 54 to placebo; 23 participants discontinued treatment (17 in the exenatide group and six in the placebo group). From a baseline-adjusted mean of 66·4 mmol/mol (95% CI 64·9-67·8 [8·2%, 8·1-8·4]), HbA1c changed by -3·2 mmol/mol (-5·0 to -1·4 [-0·3%, -0·5 to -0·1]) with exenatide and -2·1 mmol/mol (-3·7 to -0·6 [-0·2%, -0·3 to -0·1]) with placebo after 26 weeks (estimated treatment difference of -1·1 mmol/mol (-3·4 to 1·2 [-0·1%, -0·3 to 0·1]; p=0·36). Exenatide increased the number of self-reported gastrointestinal adverse events (primarily nausea [48 events among 37 patients with exenatide, nine with placebo among 9 patients]). Two serious adverse events occurred in the exenatide group, and six occurred in the placebo group (none were considered to be related to the study drug). INTERPRETATION: Short-acting exenatide does not seem to have a future as a standard add-on treatment to insulin therapy in type 1 diabetes. FUNDING: AstraZeneca.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Johansen NJ, Dejgaard TF, Lund A, et al. Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020. PMID: 32135138. doi:10.1016/S2213-8587(20)30030-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。